Atlas Trials

Tislelizumab with Azacitidine in the Treatment of R/R AML

Clinical trial NCT06586099 · WITHDRAWN

Trial details

NCT number
NCT06586099
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
WITHDRAWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Refractory AMLRelapsed Adult AML
Start date
2024-10-05
Primary completion
2025-06-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.